Merck Korea makes contract with LG to market new drug
Merck Korea, the local unit of German pharmaceutical and chemical company Merck, said yesterday that it has signed a deal with LG Life Sciences, a biopharmaceutical company, to exclusively market and sell LG’s drug Rovatitan Tab, a treatment for hypertension and hyperlipidemia.Michael Grund, managing director of Merck Korea, said, “Compared with valsartan monotherapy, Rovatitan Tab has additional blood pressure lowering effects, resulting in a strong synergy in blood pressure lowering and its powerful lipidemia improvement effects can minimize cardiovascular risk.”
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)